SCHEMBL3545667

SCHEMBL3545667

CC(C)(CNC(=O)c1ccc(N)c(Cl)c1)CN1CCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
CYP2D6 P10635 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C19 P33261 1/20 0.48
HTT P42858 1/20 0.48
GPR55 Q9Y2T6 1/20 0.48
NPC1 O15118 1/20 0.47
CNR2 P34972 3/20 0.44
CNR1 P21554 2/20 0.44
KCNH2 Q12809 1/20 0.42
CACNA1I Q9P0X4 1/20 0.42
LRRK2 Q5S007 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HTR4 Q13639 2/20 0.40
OPRK1 P41145 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3548950 0.84 HTR4 (0.52) CYP2D6NPSR1CYP2C9MAPTCNR2
SCHEMBL3543948 0.79 ALDH1A1 (0.65) LMNACYP2D6NPSR1CYP2C9CYP1A2
SCHEMBL12010064 0.79 LMNA (0.51) LMNACYP2D6NPSR1CYP2C9CYP1A2
SCHEMBL3543155 0.78 CYP2D6 (0.52) LMNACYP2D6NPSR1CYP2C9CYP1A2
SCHEMBL16882911 0.77 SMN1; SMN2 (0.57) NPC1LRRK2ALDH1A1KDM4EHSD17B10
SCHEMBL3111273 0.72 KDM4E (0.54) LMNACYP2D6NPSR1CYP2C9CYP1A2
SCHEMBL10029339 0.71 KDM4E (0.51) LMNACYP2D6CYP2C9CYP1A2MAPT
SCHEMBL872154 0.70 PTPRC (0.55) LMNACYP2D6NPSR1CYP2C9CYP1A2
SCHEMBL10079549 0.70 SMN1; SMN2 (0.56) LMNACYP2D6CYP1A2HTTALDH1A1
SCHEMBL10029215 0.70 KDM4E (0.51) LMNACYP2D6NPSR1CYP2C9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709471-B2 Compounds ASTRAZENECA AB (SE) 2010-05-04 US disclosed
EP-2046793-A2 FUSED PYRIMIDO COMPOUNDS AstraZeneca AB (SE) 2009-04-15 EP disclosed
WO-2008040951-A1 COMPOUNDS ASTRAZENECA AB (SE) 2008-04-10 WO disclosed
WO-2008040951-A1 COMPOUNDS ASTRAZENECA AB (SE) 2008-04-10 WO disclosed
WO-2008003958-A2 FUSED PYRIMIDO COMPOUNDS ASTRAZENECA AB (SE) 2008-01-10 WO disclosed
US-20080009482-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009482-A1 NOVEL COMPOUNDS CYP11B2, CYP11B1, CYP46A1 LMNA 1996/4885CYP2D6 92/4885NPSR1 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.